Skip to main content
. 2024 Feb 29;13(3):228. doi: 10.3390/antibiotics13030228

Figure 2.

Figure 2

Safety of NZ2114 and NZ2114-NPs. (A) Hemolytic effect of NZ2114 and NZ2114-NPs against mouse erythrocytes; (B) Cytotoxicity of NZ2114 and NZ2114-NPs against HaCaT cells. NZ2114-NPs: PLGA-encapsulated NZ2114 (formulation-13), Blank NPs: formulation-13 without NZ2114. (A) Red line: 5% hemolysis rate; (B) red line: 90% cell viability. Results are mean ± SD (n = 3).